과제정보
This work was supported by clinical research grant from Pusan National University Hospital in 2020.
참고문헌
- Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and metaanalysis. Lancet Infect Dis 2009;9:153-61. https://doi.org/10.1016/S1473-3099(09)70041-6
- Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J 2017;49:160803.
- World Health Organization. Global tuberculosis report 2019. WHO/CDS/TB/2019.15. Geneva: World Health Organization; 2019.
- Kim JH, Yim JJ. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913-20. https://doi.org/10.3201/eid2111.141894
- Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2018. Cheongju: Korea Centers for Disease Control and Prevention; 2019.
- Kim HJ, Bai GH, Kang MK, Kim SJ, Lee JK, Cho SI, et al. A public-private collaboration model for treatment intervention to improve outcomes in patients with tuberculosis in the private sector. Tuberc Respir Dis 2009;66:349-57. https://doi.org/10.4046/trd.2009.66.5.349
- Hong YP, Kim SJ, Lew WJ, Lee SH, Lee EK. Cohort analyses of the treatment of smear-positive pulmonary tuberculosis patients under programme conditions in Korea, 1983-1994. Int J Tuberc Lung Dis 1998;2:365-71.
- Hong YP, Kim SJ, Lee EG, Lew WJ, Bai JY. Treatment of bacillary pulmonary tuberculosis at the chest clinics in the private sector in Korea, 1993. Int J Tuberc Lung Dis 1999;3:695-702.
- Go U, Park M, Kim UN, Lee S, Han S, Lee J, et al. Tuberculosis prevention and care in Korea: evolution of policy and practice. J Clin Tuberc Other Mycobact Dis 2018;11:28-36. https://doi.org/10.1016/j.jctube.2018.04.006
- Cho KS. Tuberculosis control in the Republic of Korea. Epidemiol Health 2018;40:e2018036. https://doi.org/10.4178/epih.e2018036
- World Health Organization. Public-private mix for DOTS: towards scaling up. Geneva: World Health Organization; 2005.
- Lei X, Liu Q, Escobar E, Philogene J, Zhu H, Wang Y, et al. Public-private mix for tuberculosis care and control: a systematic review. Int J Infect Dis 2015;34:20-32. https://doi.org/10.1016/j.ijid.2015.02.015
- World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. WHO/HTM/TB/2013.2. Geneva: World Health Organization; 2013.
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2006.
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva: World Health Organization; 2008.
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva: World Health Organization; 2011.
- World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: World Health Organization; 2014.
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016.
- Lee M, Han J, Kim YR, Kwak N, Kim JH, Park O, et al. Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-2015. Int J Tuberc Lung Dis 2019;23:850-7. https://doi.org/10.5588/ijtld.18.0658
- Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43. https://doi.org/10.1016/S0140-6736(10)60410-2
- Kigozi G, Heunis C, Chikobvu P, Botha S, van Rensburg D. Factors influencing treatment default among tuberculosis patients in a high burden province of South Africa. Int J Infect Dis 2017;54:95-102. https://doi.org/10.1016/j.ijid.2016.11.407
- Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, et al. Additional drug resistance patterns among multidrug-resistant tuberculosis patients in Korea: implications for regimen design. J Korean Med Sci 2017;32:636-41. https://doi.org/10.3346/jkms.2017.32.4.636
- Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JW, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821-34. https://doi.org/10.1016/S0140-6736(18)31644-1
- Mok J, Kang H, Koh WJ, Jhun BW, Yim JJ, Kwak N, et al. Final treatment outcomes of delamanid-containing regimens in patients with MDR-/XDR-TB in South Korea. Eur Respir J 2019;54:1900811. https://doi.org/10.1183/13993003.00811-2019
- World Health Organization. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrugresistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva: World Health Organization; 2000.
- Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Multidrug-resistant tuberculosis over 20 years at a referral hospital in South Korea: trends and outcomes. Int J Tuberc Lung Dis 2019;23:174-80. https://doi.org/10.5588/ijtld.18.0295
- World Health Organization. Framework for the engagement of all health care providers in the management of drug resistant tuberculosis. WHO/HTM/TB/2015.04. Geneva: World Health Organization; 2015.
- Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914. https://doi.org/10.1371/journal.pone.0006914
- Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrugresistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis 2006;10:649-55.
- Yu MC, Chiang CY, Lee JJ, Chien ST, Lin CJ, Lee SW, et al. Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up. Clin Infect Dis 2018;67:202-10. https://doi.org/10.1093/cid/ciy066
피인용 문헌
- Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study vol.14, 2021, https://doi.org/10.2147/idr.s342964
- Importance of Public-Private Mix Collaboration in Tuberculosis Control: It Is Also Valuable in Patients with Multidrug-Resistant Tuberculosis vol.84, pp.1, 2021, https://doi.org/10.4046/trd.2020.0152
- Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline vol.84, pp.4, 2021, https://doi.org/10.4046/trd.2021.0115
- Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply vol.85, pp.1, 2021, https://doi.org/10.4046/trd.2021.0135